A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort (HAMA)

March 19, 2026 updated by: Romain Boulestreau, Centre Hospitalier de PAU
This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Malignant hypertension is the most severe form of high blood pressure, fatal if left untreated. It has not disappeared, with an increasing incidence. Patients with the disease, mainly young (35 to 55 years of age), have an unfavorable cardiovascular prognosis (14% of cardiovascular and renal events at 4 years). Despite these facts, scientific research on the subject remains limited. The definitions and diagnostic criteria have not changed since 1929, and the therapeutic recommendations remain empirical.

This first prospective and multicentric registry will increase and modernize the knowledge of the disease. From these data, diagnostic and therapeutic recommendations based on solid scientific evidence could be developed.

The investigators want to first recruit 500 patients and define their prognosis at 5 years. The impact of the patient's phenotype, type and number of target organs affected will be studied.

A modern definition, adapted to these results, could be proposed. The epidemiology of the disease, the care pathways, the target organ disorders and the management carried out in the centers will be described in detail.

Study Type

Observational

Enrollment (Estimated)

1200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Annecy, France
      • Bayonne, France, 64109
        • Recruiting
        • CH de la Côte Basque
        • Contact:
      • Bobigny, France, 93009
      • Bordeaux, France, 33000
      • Chalon-sur-Saône, France
      • Chambéry, France, 73011
      • Clermont-Ferrand, France
      • Créteil, France
      • Dinard, France, 35800
      • Grenoble, France, 38043
      • Haguenau, France, 67504
      • Le Mans, France
      • Libourne, France, 33505
      • Lille, France, 59037
      • Marseille, France, 13012
      • Marseille, France, 13385
        • Recruiting
        • Hôpital de la Conception
        • Contact:
      • Martigues, France, 13500
      • Montpellier, France
      • Nantes, France, 44800
      • Paris, France, 75015
        • Recruiting
        • Hôpital Européen Georges Pompidou
        • Contact:
      • Paris, France, 75014
        • Recruiting
        • Hopital Saint Joseph
        • Contact:
      • Paris, France, 75877
      • Paris, France
      • Paris, France
      • Pau, France, 64000
      • Pitres, France, 97159
      • Poitiers, France, 86021
      • Rennes, France, 35033
      • Rouen, France, 76000
      • Saint-Denis, France, 97400
        • Recruiting
        • Clinique sainte Clotilde
        • Contact:
      • Saint-Etienne, France, 42055
      • Saint-Nazaire, France, 44606
      • Strasbourg, France, 67000
      • Toulouse, France, 31059
      • Tours, France, 37044
      • Valenciennes, France
  • Poland
      • Warsaw, Poland
        • Not yet recruiting
        • National Institute of Cardiology
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients with malignant hypertension

Description

Inclusion Criteria:

  • Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy)
  • Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure

Exclusion Criteria:

  • Age < 18 years old
  • Patients who cannot freely give their consent, or patients who refuse to participate
  • Dialysis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
prognosis
Time Frame: 5 years
5-year prognosis for patients with malignant hypertension
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier de PAU

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 20, 2019

Primary Completion (Estimated)

September 20, 2034

Study Completion (Estimated)

September 20, 2034

Study Registration Dates

First Submitted

November 26, 2018

First Submitted That Met QC Criteria

November 26, 2018

First Posted (Actual)

November 28, 2018

Study Record Updates

Last Update Posted (Actual)

March 23, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHPAU2018/01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Hypertension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe